← Leaderboards
Don Lynn Gibbons
University Of Tx Md Anderson Can Ctr
$4,258,623
Attributed
$4,258,623
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $592.7K · FY2010–24$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,258,623 · 4
By mechanism
R37$2,657,865 · 1
K08$853,200 · 1
R21$506,944 · 1
P50$240,614 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Lauren Averett Byers$9,117,683
- Eduardo Vilar Sanchez$16,310,319
- Siyuan Zhang$7,101,087
- Scott Kopetz$13,199,822
- Seyed Javad Mirhassani Moghaddam$4,738,281
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungTumorMemberMutationMesenchymalEpithelial To Mesenchymal TransitionRegulationNeoplastic CellLung AdenocarcinomaOncogenicMicrornasMediatingPhenotypeNon-Small-Cell Lung CarcinomaCancer EtiologyComplexResistanceSignal PathwayPathway InteractionsEpithelialMutantImmune Checkpoint InhibitorBioinformaticsClinical Oncology
Grant awards (17)
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer$352,047
R37 · FY2024 · CA · contact PI
Project 3: Targeting Vulnerabilities in the Fibrotic Extracellular Matrix (ECM) of Lung Cancers$240,614
P50 · FY2024 · CA · contact PI
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer$363,165
R37 · FY2023 · CA · contact PI
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer$366,000
R37 · FY2022 · CA · contact PI
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer$10,564
R37 · FY2022 · CA · contact PI
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer$444,653
R37 · FY2021 · CA · contact PI
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer$366,000
R37 · FY2020 · CA · contact PI
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer$34,417
R37 · FY2020 · CA · contact PI
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer$355,019
R37 · FY2019 · CA · contact PI
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer$366,000
R37 · FY2018 · CA · contact PI
MicroRNA-200 family regulation by the apical-basal polarity complexes in EMT and$170,640
K08 · FY2014 · CA · contact PI
MicroRNA-200 family regulation by the apical-basal polarity complexes in EMT and$170,640
K08 · FY2013 · CA · contact PI
Notch and stem cells in lung cancer treated with erlotinib plus notch inhibitor.$253,472
R21 · FY2012 · CA · contact PI
MicroRNA-200 family regulation by the apical-basal polarity complexes in EMT and$170,640
K08 · FY2012 · CA · contact PI
Notch and stem cells in lung cancer treated with erlotinib plus notch inhibitor.$253,472
R21 · FY2011 · CA · contact PI
MicroRNA-200 family regulation by the apical-basal polarity complexes in EMT and$170,640
K08 · FY2011 · CA · contact PI
MicroRNA-200 family regulation by the apical-basal polarity complexes in EMT and$170,640
K08 · FY2010 · CA · contact PI